Literature DB >> 23013600

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.

Bakhtawar K Mahmoodi1, Kunihiro Matsushita, Mark Woodward, Peter J Blankestijn, Massimo Cirillo, Takayoshi Ohkubo, Peter Rossing, Mark J Sarnak, Bénédicte Stengel, Kazumasa Yamagishi, Kentaro Yamashita, Luxia Zhang, Josef Coresh, Paul E de Jong, Brad C Astor.   

Abstract

BACKGROUND: Hypertension is the most prevalent comorbidity in individuals with chronic kidney disease. However, whether the association of the kidney disease measures, estimated glomerular filtration rate (eGFR) and albuminuria, with mortality or end-stage renal disease (ESRD) differs by hypertensive status is unknown.
METHODS: We did a meta-analysis of studies selected according to Chronic Kidney Disease Prognosis Consortium criteria. Data transfer and analyses were done between March, 2011, and June, 2012. We used Cox proportional hazards models to estimate the hazard ratios (HR) of mortality and ESRD associated with eGFR and albuminuria in individuals with and without hypertension.
FINDINGS: We analysed data for 45 cohorts (25 general population, seven high-risk, and 13 chronic kidney disease) with 1,127,656 participants, 364,344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts. All-cause mortality risk was 1·1-1·2 times higher in individuals with hypertension than in those without hypertension at preserved eGFR. A steeper relative risk gradient in individuals without hypertension than in those with hypertension at eGFR range 45-75 mL/min per 1·73 m(2) led to much the same mortality risk at lower eGFR. With a reference eGFR of 95 mL/min per 1·73 m(2) in each group to explicitly assess interaction, adjusted HR for all-cause mortality at eGFR 45 mL/min per 1·73 m(2) was 1·77 (95% CI 1·57-1·99) in individuals without hypertension versus 1·24 (1·11-1·39) in those with hypertension (p for overall interaction=0·0003). Similarly, for albumin-creatinine ratio of 300 mg/g (vs 5 mg/g), HR was 2·30 (1·98-2·68) in individuals without hypertension versus 2·08 (1·84-2·35) in those with hypertension (p for overall interaction=0·019). We recorded much the same results for cardiovascular mortality. The associations of eGFR and albuminuria with ESRD, however, did not differ by hypertensive status. Results for chronic kidney disease cohorts were similar to those for general and high-risk population cohorts.
INTERPRETATION: Chronic kidney disease should be regarded as at least an equally relevant risk factor for mortality and ESRD in individuals without hypertension as it is in those with hypertension. FUNDING: US National Kidney Foundation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23013600      PMCID: PMC3993095          DOI: 10.1016/S0140-6736(12)61272-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  33 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease.

Authors:  Csaba P Kovesdy; Bhairvi K Trivedi; Kamyar Kalantar-Zadeh; John E Anderson
Journal:  Nephrol Dial Transplant       Date:  2006-01-18       Impact factor: 5.992

3.  Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained?

Authors:  H Borsboom; L Smans; M J M Cramer; J C Kelder; M P Kooistra; P F Vos; B C van Jaarsveld
Journal:  Neth J Med       Date:  2005-11       Impact factor: 1.422

4.  Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.

Authors:  Catherine M Clase; Peggy Gao; Sheldon W Tobe; Matthew J McQueen; Anja Grosshennig; Koon K Teo; Salim Yusuf; Johannes F E Mann
Journal:  Ann Intern Med       Date:  2011-03-01       Impact factor: 25.391

Review 5.  Screening for chronic kidney disease: which strategy?

Authors:  Stein I Hallan; Paul Stevens
Journal:  J Nephrol       Date:  2010 Mar-Apr       Impact factor: 3.902

6.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

Authors:  Steven J Chadban; Esther M Briganti; Peter G Kerr; David W Dunstan; Timothy A Welborn; Paul Z Zimmet; Robert C Atkins
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

8.  Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors.

Authors:  Gülmisal Güder; Stefan Frantz; Johann Bauersachs; Bruno Allolio; Christoph Wanner; Michael T Koller; Georg Ertl; Christiane E Angermann; Stefan Störk
Journal:  Circ Heart Fail       Date:  2009-09-24       Impact factor: 8.790

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.

Authors:  Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Jackson Wright; Larry Appel; Tom Greene; Adeera Levin; Ognjenka Djurdjev; David C Wheeler; Martin J Landray; John N Townend; Jonathan Emberson; Laura E Clark; Alison Macleod; Angharad Marks; Tariq Ali; Nicholas Fluck; Gordon Prescott; David H Smith; Jessica R Weinstein; Eric S Johnson; Micah L Thorp; Jack F Wetzels; P J Blankestijn; A D van Zuilen; Vandana Menon; Mark Sarnak; Gerald Beck; Florian Kronenberg; Barbara Kollerits; Marc Froissart; Benedicte Stengel; Marie Metzger; Giuseppe Remuzzi; Piero Ruggenenti; Annalisa Perna; H J Lambers Heerspink; Barry Brenner; Dick de Zeeuw; Peter Rossing; Hans-Henrik Parving; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

View more
  149 in total

1.  Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study.

Authors:  Todd H Driver; Ronit Katz; Joachim H Ix; Jared W Magnani; Carmen A Peralta; Chirag R Parikh; Linda Fried; Anne B Newman; Stephen B Kritchevsky; Mark J Sarnak; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2014-03-18       Impact factor: 8.860

2.  An Age-Calibrated Definition of Chronic Kidney Disease: Rationale and Benefits.

Authors:  Pierre Delanaye; Richard J Glassock; Hans Pottel; Andrew D Rule
Journal:  Clin Biochem Rev       Date:  2016-02

3.  Inhibition of SET Domain-Containing Lysine Methyltransferase 7/9 Ameliorates Renal Fibrosis.

Authors:  Kensuke Sasaki; Shigehiro Doi; Ayumu Nakashima; Taisuke Irifuku; Kyoko Yamada; Keiko Kokoroishi; Toshinori Ueno; Toshiki Doi; Eisuke Hida; Koji Arihiro; Nobuoki Kohno; Takao Masaki
Journal:  J Am Soc Nephrol       Date:  2015-06-04       Impact factor: 10.121

4.  Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Ana C Ricardo; Cheryl A Anderson; Wei Yang; Xiaoming Zhang; Michael J Fischer; Laura M Dember; Jeffrey C Fink; Anne Frydrych; Nancy G Jensvold; Eva Lustigova; Lisa C Nessel; Anna C Porter; Mahboob Rahman; Julie A Wright Nunes; Martha L Daviglus; James P Lash
Journal:  Am J Kidney Dis       Date:  2014-11-20       Impact factor: 8.860

Review 5.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

6.  Renal hyperfiltration as a novel marker of all-cause mortality.

Authors:  Minseon Park; Eunsil Yoon; Youn-Hee Lim; Ho Kim; Jinwook Choi; Hyung-Jin Yoon
Journal:  J Am Soc Nephrol       Date:  2014-10-24       Impact factor: 10.121

Review 7.  A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury.

Authors:  Matthew T James; Morgan E Grams; Mark Woodward; C Raina Elley; Jamie A Green; David C Wheeler; Paul de Jong; Ron T Gansevoort; Andrew S Levey; David G Warnock; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2015-05-11       Impact factor: 8.860

8.  Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective.

Authors:  George Bakris
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

Review 9.  Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options.

Authors:  Eva E Vink; Rosa L de Jager; Peter J Blankestijn
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

10.  Lifetime Risk of Stage 3-5 CKD in a Community-Based Sample in Iceland.

Authors:  Lesley A Inker; Hocine Tighiouart; Thor Aspelund; Vilmundur Gudnason; Tamara Harris; Olafur S Indridason; Runolfur Palsson; Shani Shastri; Andrew S Levey; Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.